These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 11888075

  • 21. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
    Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B, Ehninger G, Schleyer E.
    Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
    [Abstract] [Full Text] [Related]

  • 22. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
    Xu Y, Wahner AE, Nguyen PL.
    Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.
    Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376
    [Abstract] [Full Text] [Related]

  • 28. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.
    Clin Cancer Res; 2004 Aug 01; 10(15):5065-71. PubMed ID: 15297408
    [Abstract] [Full Text] [Related]

  • 29. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
    Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F, Cortes JE.
    Cancer; 2004 Jan 01; 100(1):116-21. PubMed ID: 14692031
    [Abstract] [Full Text] [Related]

  • 30. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Drummond MW, Holyoake TL.
    Cancer; 2003 Oct 15; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Imatinib therapy for patients with chronic myelogenous leukemia].
    Usui N.
    Gan To Kagaku Ryoho; 2005 Mar 15; 32(3):297-303. PubMed ID: 15791812
    [Abstract] [Full Text] [Related]

  • 33. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Clin Cancer Res; 2006 Dec 15; 12(24):7374-9. PubMed ID: 17189410
    [Abstract] [Full Text] [Related]

  • 34. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J.
    Cancer; 2003 Nov 01; 98(9):1905-11. PubMed ID: 14584073
    [Abstract] [Full Text] [Related]

  • 35. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
    Espinet B, Oliveira AC, Boqué C, Domingo A, Alonso E, Solé F.
    Haematologica; 2005 Apr 01; 90(4):556-8. PubMed ID: 15820956
    [Abstract] [Full Text] [Related]

  • 36. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
    Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J.
    Leuk Res; 2004 Jun 01; 28(6):613-8. PubMed ID: 15120938
    [Abstract] [Full Text] [Related]

  • 37. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R.
    Clin Cancer Res; 2002 May 01; 8(5):935-42. PubMed ID: 12006504
    [Abstract] [Full Text] [Related]

  • 38. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA, Pan Q, Ladanyi M, Steinherz PG.
    Cancer; 2003 Dec 15; 98(12):2643-50. PubMed ID: 14669284
    [Abstract] [Full Text] [Related]

  • 39. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A, Kriener S, Engels K, Staib P, Ollig ES, Keller C, Fokkema S, Griesshammer M, Waller CF, Ottmann OG, Hansmann ML.
    Histopathology; 2005 May 15; 46(5):540-50. PubMed ID: 15842636
    [Abstract] [Full Text] [Related]

  • 40. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.
    Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Höfler G, Haas OA, Linkesch W.
    Blood; 2002 Jan 01; 99(1):381-3. PubMed ID: 11756197
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.